Date: 2015-03-05
Type of information: Establishment of a new subsidiary in the US
Compound:
Company: Adocia (France)
Therapeutic area: Metabolic diseases
Type agreement: establishment of a new subsidiary in the US
Action mechanism:
Disease:
Details: * On March 5 2015, Adocia announced the creation of a subsidiary in the USA, Adocia Incorporated, and the accompanying appointments of Simon Bruce, MD and Stephen Daly. Opening a US subsidiary is a key step in Adocia’s strategy, the USA are currently the primary market for its products. Adocia has developed BioChaperone® pipeline products in order to improve the insulin based treatments for diabetes, monoclonal antibodies and growth factors for the diabetic foot ulcer healing. Last December 2014, Adocia announced an alliance with Eli Lilly
to co-develop BioChaperone Lispro, which is one of its products for the treatment of diabetes. « The opening of a US subsidiary is crucial in order to increase our efforts on this priority market. Our development axis are to intensify our efforts in partnerships, to build relationships with the main key opinion leaders, specialized in the diabetes as well as in the wound healing fields in order to assert the medical benefit of our innovative formulations and eventually increase links with the US financial community, » says Gérard Soula, CEO of Adocia.
Two employees are already appointed, Simon Bruce, M.D., Chief Medical Officer and Stephen Daly, US Commercial Lead who is in charge of the business development in the USA and also of the US investors relations. Dr. Bruce, who originally trained in endocrine clinical research at the National Institutes of Health in Bethesda, MD, has over 15 years of experience drug development and registrational drug trials. In his last job at Halozyme Pharmaceuticals, Dr Bruce held a position as an Executive Medical Director working on the ultra-rapid insulin program. He was in charge of the regulatory strategy and led numerous interactions with the Food and Drug Administration (FDA). Previously at Amylin Pharmaceuticals, he was in charge of the phase 3 studies and safety analysis in the development in the USA of Bydureon, which is a once-weekly GLP-1 analog injectable formulation.
Stephen Daly has 24 years of experience in commercialization and business development for pharmaceutical and biotech products across multiple therapeutic categories. Most recently, he served as the Vice President of Commercial at Halozyme Therapeutics for their ultra-rapid insulin program. Stephen Daly’s experience in the diabetes field also includes several years at Amylin Pharmaceuticals in marketing and brand leadership for Byetta® and Symlin®.
.
Financial terms:
Latest news:
